Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A fixed-dose co-formulated antiretroviral drug containing elvitegravir, a new integrase strand transfer inhibitor, boosted by a novel pharmacokinetic enhancer cobicistat, and further containing the nucleoside pair of tenofovir and emtricitabine was recently approved by the U.S. Food and Drug Administration as a single-tablet, once-a-day treatment of HIV-1 infection in antiretroviral therapy-naive adults. This drug was found to be noninferior to two currently preferred antiretroviral regimens in clinical practice in two large, 48-week, phase III studies. Renal adverse effects limit its use to those with creatinine clearance > 70 mL/min; its considerable drug interaction potential requires care and attention when used. Nevertheless, the availability of this fixed-dose combination product is an important progress in the management of HIV infection for a number of reasons: It provides a third option for a onepill, once-a-day antiretroviral regimen; it is the first such regimen that is not based on a non-nucleoside reverse transcriptase inhibitor; and it provides an alternative to ritonavir for the pharmaco-enhancement of other antiretroviral drugs.

Original languageEnglish (US)
Pages (from-to)765-771
Number of pages7
JournalDrugs of Today
Volume48
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

HIV Infections
Tenofovir
Pharmaceutical Preparations
Integrases
Ritonavir
Reverse Transcriptase Inhibitors
United States Food and Drug Administration
Drug Interactions
Nucleosides
Tablets
HIV-1
Creatinine
Therapeutics
Pharmacokinetics
Kidney
Cobicistat
JTK 303
Emtricitabine

Keywords

  • Anti-HIV agent
  • Cobicistat/elvitegravir/tenofovir disoproxil fumarate/emtricitabine
  • Fixed-dose combination
  • Quad

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection. / Temesgen, Zelalem.

In: Drugs of Today, Vol. 48, No. 12, 12.2012, p. 765-771.

Research output: Contribution to journalArticle

@article{adebbdd42e9a46cfa983cc7419eea91d,
title = "Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection",
abstract = "A fixed-dose co-formulated antiretroviral drug containing elvitegravir, a new integrase strand transfer inhibitor, boosted by a novel pharmacokinetic enhancer cobicistat, and further containing the nucleoside pair of tenofovir and emtricitabine was recently approved by the U.S. Food and Drug Administration as a single-tablet, once-a-day treatment of HIV-1 infection in antiretroviral therapy-naive adults. This drug was found to be noninferior to two currently preferred antiretroviral regimens in clinical practice in two large, 48-week, phase III studies. Renal adverse effects limit its use to those with creatinine clearance > 70 mL/min; its considerable drug interaction potential requires care and attention when used. Nevertheless, the availability of this fixed-dose combination product is an important progress in the management of HIV infection for a number of reasons: It provides a third option for a onepill, once-a-day antiretroviral regimen; it is the first such regimen that is not based on a non-nucleoside reverse transcriptase inhibitor; and it provides an alternative to ritonavir for the pharmaco-enhancement of other antiretroviral drugs.",
keywords = "Anti-HIV agent, Cobicistat/elvitegravir/tenofovir disoproxil fumarate/emtricitabine, Fixed-dose combination, Quad",
author = "Zelalem Temesgen",
year = "2012",
month = "12",
doi = "10.1358/dot.2012.48.12.1895682",
language = "English (US)",
volume = "48",
pages = "765--771",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "12",

}

TY - JOUR

T1 - Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection

AU - Temesgen, Zelalem

PY - 2012/12

Y1 - 2012/12

N2 - A fixed-dose co-formulated antiretroviral drug containing elvitegravir, a new integrase strand transfer inhibitor, boosted by a novel pharmacokinetic enhancer cobicistat, and further containing the nucleoside pair of tenofovir and emtricitabine was recently approved by the U.S. Food and Drug Administration as a single-tablet, once-a-day treatment of HIV-1 infection in antiretroviral therapy-naive adults. This drug was found to be noninferior to two currently preferred antiretroviral regimens in clinical practice in two large, 48-week, phase III studies. Renal adverse effects limit its use to those with creatinine clearance > 70 mL/min; its considerable drug interaction potential requires care and attention when used. Nevertheless, the availability of this fixed-dose combination product is an important progress in the management of HIV infection for a number of reasons: It provides a third option for a onepill, once-a-day antiretroviral regimen; it is the first such regimen that is not based on a non-nucleoside reverse transcriptase inhibitor; and it provides an alternative to ritonavir for the pharmaco-enhancement of other antiretroviral drugs.

AB - A fixed-dose co-formulated antiretroviral drug containing elvitegravir, a new integrase strand transfer inhibitor, boosted by a novel pharmacokinetic enhancer cobicistat, and further containing the nucleoside pair of tenofovir and emtricitabine was recently approved by the U.S. Food and Drug Administration as a single-tablet, once-a-day treatment of HIV-1 infection in antiretroviral therapy-naive adults. This drug was found to be noninferior to two currently preferred antiretroviral regimens in clinical practice in two large, 48-week, phase III studies. Renal adverse effects limit its use to those with creatinine clearance > 70 mL/min; its considerable drug interaction potential requires care and attention when used. Nevertheless, the availability of this fixed-dose combination product is an important progress in the management of HIV infection for a number of reasons: It provides a third option for a onepill, once-a-day antiretroviral regimen; it is the first such regimen that is not based on a non-nucleoside reverse transcriptase inhibitor; and it provides an alternative to ritonavir for the pharmaco-enhancement of other antiretroviral drugs.

KW - Anti-HIV agent

KW - Cobicistat/elvitegravir/tenofovir disoproxil fumarate/emtricitabine

KW - Fixed-dose combination

KW - Quad

UR - http://www.scopus.com/inward/record.url?scp=84871597625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871597625&partnerID=8YFLogxK

U2 - 10.1358/dot.2012.48.12.1895682

DO - 10.1358/dot.2012.48.12.1895682

M3 - Article

VL - 48

SP - 765

EP - 771

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 12

ER -